Last reviewed · How we verify
Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy
The study proceeds with prospective, randomized, open and controlled clinical trials. The subject of the investigator's study was the first patient diagnosed with dilated cardiomyopathy. Subjects who agreed to participate in the study and were determined to meet the selection / exclusion criteria were randomly assigned to each group, and the experimental group was treated with 20 mg of olmesartan and 5 mg of rosuvastatin for 6 months, and the control group is treated with 40 mg of valsartan and 5 mg of rosuvastatin.
Details
| Lead sponsor | Dong-A University |
|---|---|
| Phase | NA |
| Status | UNKNOWN |
| Enrolment | 40 |
| Start date | Sun Dec 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Dec 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Dilated Cardiomyopathy
Interventions
- FDG PET
Countries
South Korea